Low Dose Naltrexone (LDN) is a novel approach to decrease release of inflammatory substances, reduce nerve cell inflammation and autoimmune mediators.
Naltrexone belongs to a class of drugs known as opioid agonists. Naltrexone blocks opiate drugs from binding to the opioid receptors, which can result in increased endorphin and enkephalin release. Therefore, this results in reduced: 1. signaling and release of inflammatory substances, 2. nerve cell inflammation and 3. autoimmune mediators.
Patients that may benefit from LDN therapy?